Business
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The objective of this meeting was to review results from the Phase 2 study of zervimesine
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Jbo6FiAF3erk7pleciP5Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Jbo6FiAF3erk7pleciP5Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOA--/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"- Positive Discussion on Path Forward for Registrational Program -","length":66,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026. The objective of this meeting was to review results from the Phase 2 study of zervimesine (CT1812) and discuss the design and endpoints of a registrational study in dementia with Lewy bodies (DLB) patients with psychosis.","length":564,"tagName":"p"},{"type":"text","content":"Lisa Ricciardi, president and CEO of Cognition, stated, “Yesterday we held a productive meeting with the FDA. The agency and we discussed the results from our Phase 2 COG1201 ‘SHIMMER’ Study in DLB and our proposed plan to advance zervimesine into a registrational program. We believe we have a path forward for the development of zervimesine for the treatment of DLB psychosis. We look forward to reviewing the FDA’s formal minutes in June.”","length":442,"tagName":"p"},{"type":"text","content":"About Cognition Therapeutics: Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company has led pioneering research into the underlying mechanisms of degenerative nerve d...